Pharmaceutical Commerce June 2026

By prioritizing solutions such as reusable plastic pallets, pharmaceutical companies can ensure that their high-value innovations are protected by equally innovative packaging.

The US DSCSA requires digital drug traceability to ensure patient safety, but supply chains face data errors; deploying AI adds an intelligent compliance layer to automate process tracking and protect drug access.

Cash pay is re-emerging as biopharma brands rethink insurance barriers, patient access, and affordability in a fragmented payer market.

High copays, restrictive networks, and travel distances leave many rural Americans facing steep barriers to prescription access.

There is never a quiet moment to step into a new role, and joining Pharmaceutical Commerce as editor has been no exception.

The industry is asking harder questions about how therapies reach people, who can afford them, and what it will take to close the gaps that remain.

Decision intelligence helps pharma unify small molecule and cell and gene therapy supply chains through AI-driven, automated decision-making.

For drugs already on the market, there may be little companies can do to limit business impact; however, for new development drugs, there are some critical considerations.

Manasi Salgaonkar examines how accurate class of trade research enables precise pricing, contract eligibility, and compliance.

How the zero-prefix collision will disrupt reimbursement, patient access, brand protection and market intelligence — and what commercial leaders must do before 2033.

Building climate-resilient cold chains with AI, smarter logistics, and collaboration to ensure safe delivery in a warming world.